Company Sector
TCR-T Therapy
TCR-T Therapy includes companies engineering T-cell receptors to recognize specific antigens presented by tumor or diseased cells. It is a specialized cell-therapy category with particular relevance in solid tumors and antigen-defined precision immuno-oncology.
Why watch TCR-T Therapy
This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.
Latest TCR-T Therapy news
The latest feed items from companies currently grouped under TCR-T Therapy.
- 01
LEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Source: Legend Biotech Corporation
- 02
LEGNLegend Biotech Announces CEO Transition
Source: Legend Biotech Corporation
- 03
LEGNLegend Biotech Corporation Announces Pricing of Public Offering
Source: Legend Biotech Corporation
- 04
LEGNLegend Biotech Corporation Announces Proposed Public Offering
Source: Legend Biotech Corporation
- 05
- 06
- 07
LEGNLegend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Source: Legend Biotech Corporation
- 08
LEGNLegend Biotech Announces Presentations at ASCO 2026
Source: Legend Biotech Corporation
- 09
LEGNLegend Biotech Reports First Quarter 2026 Results and Recent Highlights
Source: Legend Biotech Corporation
- 10
LEGNLegend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Source: Legend Biotech Corporation
- 11
LEGNLegend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Source: Legend Biotech Corporation
- 12
LEGNLegend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Source: Legend Biotech Corporation
- 13
LEGNLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Source: Legend Biotech Corporation
- 14
LEGNLegend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Source: Legend Biotech Corporation
- 15
LEGNLegend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
Source: Legend Biotech Corporation
- 16
LEGNLegend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: Legend Biotech Corporation
- 17
- 18
LEGNLegend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
Source: Legend Biotech Corporation
- 19
ADAPAdaptimmune Announces Changes to Board and Executive Leadership Team
Source: Adaptimmune Therapeutics plc
- 20
LEGNLegend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Source: Legend Biotech Corporation
Companies in TCR-T Therapy
3 companies tagged with TCR-T Therapy.
Frequently Asked Questions
What does the TCR-T Therapy sector include?
TCR-T Therapy includes companies engineering T-cell receptors to recognize specific antigens presented by tumor or diseased cells. It is a specialized cell-therapy category with particular relevance in solid tumors and antigen-defined precision immuno-oncology.
How many companies are currently tagged with TCR-T Therapy?
3 companies are currently grouped under TCR-T Therapy on BioPharmSignal.
Which companies are most visible in the TCR-T Therapy group right now?
ADAP, LEGN, TCRX are among the companies currently shown on this sector page.
How can I watch news for TCR-T Therapy?
Use the Watch button on this page to subscribe to TCR-T Therapy headlines and related company updates through your BioPharmSignal saved filters.
What kinds of updates usually appear for TCR-T Therapy?
The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in TCR-T Therapy.